Denosumab versus romosozumab for postmenopausal osteoporosis treatment

Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment. However, no studies have directly compared their therapeutic effects or safety in postmenopausal osteoporosis. This retrospective observational...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayakawa, Tomonori, Miyazaki, Akiko, Saito, Makoto, Suzuki, Takako, Takahashi, Jun, Nakamura, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175428/
https://www.ncbi.nlm.nih.gov/pubmed/34083636
http://dx.doi.org/10.1038/s41598-021-91248-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175428/
https://www.ncbi.nlm.nih.gov/pubmed/34083636
http://dx.doi.org/10.1038/s41598-021-91248-6

Ejemplares similares